Moleculin Biotech Inc.
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Moleculin Biotech Inc. (Nasdaq: MBRX) is a US clinical-stage biopharmaceutical company developing drug candidates for hard-to-treat tumors and viruses. Its lead candidate Annamycin is a next-generation anthracycline designed to avoid the cardiotoxicity of traditional anthracyclines, being studied in the MIRACLE Phase 2B/3 trial for relapsed or refractory acute myeloid leukemia (AML). The company has no revenue and depends on continuous equity financing; in 2025 it fell out of compliance with Nasdaq's $2.5 million minimum stockholders' equity rule, received a delisting determination in November 2025, and regained compliance in January 2026.
02 / Moleculin Biotech Inc. FAILURE REASONS
Failure reasons
Moleculin's troubles follow the classic clinical-stage biotech trap: no revenue, sizable ongoing losses and persistent cash burn, forcing repeated dilutive equity offerings to fund trials. In May 2025 Nasdaq notified it of non-compliance with the $2.5 million stockholders' equity rule; an extension to November 19, 2025 was granted, but a delisting determination followed on November 20, 2025. The company appealed, effected a 1-for-25 reverse stock split on December 1, 2025, and regained compliance in January 2026 — while warning it still needs significant additional financing with no commitments in place.
03 / EVENT HISTORY
Events in the structured record
- Nasdaq compliance crisis
Moleculin fails Nasdaq's $2.5M stockholders' equity rule; receives a delisting determination on November 20, 2025 and appeals; effects a 1-for-25 reverse stock split on December 1, 2025.
- Compliance regained
Moleculin regains Nasdaq compliance in January 2026 and the delisting hearing is cancelled; the MIRACLE AML trial continues while the company warns of further financing needs.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Moleculin has no revenue and reports sizable ongoing losses with persistent cash burn, depending on continued equity financing (warrant exercises, share offerings).
- 02
In 2025 it conducted a 1-for-25 reverse stock split and multiple dilutive financings to maintain its Nasdaq listing. No audited loss figure with disclosed subject, period and basis was extracted — per-share and period figures in filings were not consolidated into a citable total.